Investors Buy High Volume of Put Options on Amedisys (AMED)

Share on StockTwits

Amedisys Inc (NASDAQ:AMED) saw unusually large options trading activity on Monday. Stock investors bought 2,242 put options on the stock. This is an increase of approximately 1,679% compared to the average daily volume of 126 put options.

Amedisys stock opened at $100.89 on Tuesday. Amedisys has a 52-week low of $45.60 and a 52-week high of $127.38. The firm has a market cap of $3.13 billion, a PE ratio of 45.65, a price-to-earnings-growth ratio of 1.50 and a beta of 1.00. The company has a quick ratio of 1.21, a current ratio of 1.21 and a debt-to-equity ratio of 0.30.

Amedisys (NASDAQ:AMED) last released its earnings results on Monday, October 29th. The health services provider reported $0.95 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.77 by $0.18. Amedisys had a net margin of 4.46% and a return on equity of 20.11%. The business had revenue of $417.34 million during the quarter, compared to analyst estimates of $411.05 million. During the same quarter in the prior year, the firm earned $0.56 earnings per share. The company’s revenue for the quarter was up 11.7% compared to the same quarter last year. Equities research analysts anticipate that Amedisys will post 3.39 EPS for the current fiscal year.

In related news, insider David B. Pearce sold 398 shares of the business’s stock in a transaction on Tuesday, September 25th. The shares were sold at an average price of $121.71, for a total value of $48,440.58. Following the completion of the sale, the insider now owns 11,818 shares of the company’s stock, valued at approximately $1,438,368.78. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. 2.60% of the stock is currently owned by insiders.

Several institutional investors have recently added to or reduced their stakes in the company. BlackRock Inc. grew its holdings in shares of Amedisys by 7.5% during the second quarter. BlackRock Inc. now owns 5,382,005 shares of the health services provider’s stock worth $459,945,000 after buying an additional 377,153 shares in the last quarter. Rothschild Asset Management Inc. boosted its position in shares of Amedisys by 0.3% during the 2nd quarter. Rothschild Asset Management Inc. now owns 447,262 shares of the health services provider’s stock valued at $38,223,000 after acquiring an additional 1,278 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its position in shares of Amedisys by 9.0% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 202,546 shares of the health services provider’s stock valued at $17,310,000 after acquiring an additional 16,677 shares during the last quarter. Acadian Asset Management LLC boosted its position in shares of Amedisys by 148.0% during the 2nd quarter. Acadian Asset Management LLC now owns 191,162 shares of the health services provider’s stock valued at $16,338,000 after acquiring an additional 114,077 shares during the last quarter. Finally, Sei Investments Co. boosted its position in shares of Amedisys by 762.0% during the 2nd quarter. Sei Investments Co. now owns 123,582 shares of the health services provider’s stock valued at $10,562,000 after acquiring an additional 109,246 shares during the last quarter. 93.19% of the stock is owned by institutional investors and hedge funds.

Several brokerages recently commented on AMED. Craig Hallum lowered shares of Amedisys from a “buy” rating to a “hold” rating and cut their price target for the stock from $116.00 to $104.00 in a report on Friday. BidaskClub lowered shares of Amedisys from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 16th. Robert W. Baird boosted their price target on shares of Amedisys from $105.00 to $120.00 and gave the stock a “neutral” rating in a report on Thursday, October 11th. SunTrust Banks boosted their price target on shares of Amedisys to $130.00 and gave the stock a “buy” rating in a report on Thursday, October 11th. Finally, Cantor Fitzgerald boosted their price target on shares of Amedisys from $117.00 to $125.00 and gave the stock a “neutral” rating in a report on Thursday, October 11th. Six equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $97.08.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, and aides for its patients to complete their important personal tasks.

Featured Story: Trading Strategy Examples and Plans

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply